Seventy-five percent of bladder cancers are non-muscle invasive. The treatment strategy includes the transurethral resection of bladder tumor (TURB) followed by intravesical immunotherapy with the bacillus of Calmette-Guerin (BCG) or chemotherapy, depending on the grade of bladder tumor. Despite a proper BCG intravesical instillations schedule, up to 40% of patients present a failure within 2 years. The aim of this retrospective study was to investigate the predictive factors in the response to BCG in patients with a high-grade non-muscle invasive bladder cancer diagnosis.
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer / Ferro, Matteo; Barone, Biagio; Crocetto, Felice; Lucarelli, Giuseppe; Busetto, Gian Maria; Del Giudice, Francesco; Maggi, Martina; Crocerossa, Fabio; Cantiello, Francesco; Damiano, Rocco; Borghesi, Marco; Bove, Pier Luigi; Papalia, Rocco; Mari, Andrea; Luzzago, Stefano; Soria, Francesco; Marchioni, Michele; La Civita, Evelina; Terracciano, Daniela; Mistretta, Francesco Alessandro; Piccinelli, Mattia; Marmiroli, Andrea; Russo, Giorgio Ivan; Schips, Luigi; Hurle, Rodolfo; Contieri, Roberto; Perdonà, Sisto; Del Prete, Paola; Mirone, Vincenzo; Tataru, Octavian Sabin; Musi, Gennaro; Montanari, Emanuele; de Cobelli, Ottavio; Vartolomei, Mihai Dorin. - In: UROLOGIC ONCOLOGY. - ISSN 1078-1439. - 40:11(2022), pp. 13-20. [10.1016/j.urolonc.2022.05.016]
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer
Lucarelli, Giuseppe;Busetto, Gian Maria;Del Giudice, Francesco;Maggi, Martina;Mari, Andrea;Schips, Luigi;
2022
Abstract
Seventy-five percent of bladder cancers are non-muscle invasive. The treatment strategy includes the transurethral resection of bladder tumor (TURB) followed by intravesical immunotherapy with the bacillus of Calmette-Guerin (BCG) or chemotherapy, depending on the grade of bladder tumor. Despite a proper BCG intravesical instillations schedule, up to 40% of patients present a failure within 2 years. The aim of this retrospective study was to investigate the predictive factors in the response to BCG in patients with a high-grade non-muscle invasive bladder cancer diagnosis.| File | Dimensione | Formato | |
|---|---|---|---|
|
Ferro_Predictive clinico-pathological_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
690.96 kB
Formato
Adobe PDF
|
690.96 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
